We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New Ultrafast 5-Minute PCR Technology Faster Than Self-Diagnosis Kits

By LabMedica International staff writers
Posted on 24 Feb 2023

PCR technology which detects target nucleic acids by amplifying the DNA amount has witnessed significant progress in the life sciences field since it was first developed in 1984. More...

The molecular diagnostics technology achieved public familiarity during the COVID-19 pandemic, as PCR is capable of detecting nucleic acids that identify the COVID-19 virus. However, the technical nature of the PCR test makes it impossible for the results to be delivered before one to two hours due to its need for repeated temperature cycles (60~95℃). Now, a new ultrafast PCR technology uses photothermal nanomaterials to shorten the test time by 10-fold, as compared with the time taken by the existing test. The new method can be completed in five minutes and delivers a diagnostic performance that is similar to that of the existing test method.

Photothermal nanomaterials generate heat immediately upon light irradiation and rapidly increase in temperature, although the performance can be difficult to maintain due to their low stability. A research team at Korea Institute of Science and Technology (KIST) has developed a polymer composite that physically holds photothermal nanomaterials and can overcome their instability. By applying it to a PCR system, the team has developed a compact PCR system without a heat plate. Additionally, the researchers have implemented a multiplex diagnostic technology that detects several genes simultaneously, enabling it to distinguish several types of COVID-19 variants in a single reaction.

"Through additional research, we plan to miniaturize the developed ultrafast PCR technology this year, to develop a device that can be utilized anywhere," said Dr. Sang Kyung Kim, Director at the Center for Augmented Safety System with Intelligence, Sensing of the KIST. "While maintaining the strength of PCR as an accurate diagnostic method, we will increase its convenience, field applicability, and promptness, by which we expect that it will become a precision diagnostic device that can be used at primary local clinics, pharmacies, and even at home. In addition, PCR technology is a universal molecular diagnostic technology that can be applied to various diseases other than infectious diseases, so it will become more applicable."

Related Links:
KIST


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.